Sanofi Faces Mylan Lawsuit Over Generic Diabetes Drug Delay

French pharmaceutical company Sanofi S.A. is facing a new lawsuit alleging it engaged in anticompetitive conduct to protect its monopoly over an injectable form of a diabetes drug.

The lead plaintiff, Mylan Pharmaceuticals Inc., claims Sanofi violated antitrust laws by delaying regulatory approval of Mylan’s generic insulin drug in order to shield competition for its insulin products, Lantus and Toujeo, according to a complaint filed Wednesday in the US District Court for the Western District of Pennsylvania.

Sanofi-Aventis U.S. LLC is also listed as a defendant, along with Aventis Pharma S.A. and Sanofi-Aventis Puerto Rico Inc.

Sanofi delayed the ...